Core Viewpoint - Federal Pharmaceutical's subsidiary, Zhuhai Federal Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration of China for the launch of Levofloxacin Eye Drops, enhancing the company's position in the ophthalmic infection treatment market [1] Group 1: Product Approval - Levofloxacin Eye Drops (0.488% concentration, 5ml: 24.4mg) has been granted approval with the registration number H20256135 [1] - The drug is a third-generation fluoroquinolone antibiotic that inhibits bacterial DNA synthesis, showing significant antibacterial activity against various Gram-positive and Gram-negative bacteria [1] Group 2: Clinical Applications - Levofloxacin Eye Drops are widely used for treating conditions such as blepharitis, meibomian gland inflammation, dacryocystitis, conjunctivitis, meibomianitis, and keratitis, as well as for sterile treatment during ophthalmic surgeries [1] Group 3: Market Impact - The approval of Levofloxacin Eye Drops will further expand Federal Pharmaceutical's ophthalmic product portfolio and strengthen its competitive position in the field of ophthalmic infection treatment [1] - The product is classified as a Category A drug in the National Medical Insurance Directory (2024 edition), indicating its importance in the healthcare market [1] Group 4: Future Outlook - The company is committed to advancing new product development to provide comprehensive and high-quality medication solutions for clinical use, which is expected to generate greater returns for the company and its shareholders [1]
联邦制药(03933)：左氧氟沙星滴眼液通过中国国家药品监督管理局上市审批